This study also showed that MSI-CRCs have different immune microenvironments comprising of tumor neoantigen-specific CD8 T cells, which could be used to further advance immunotherapy in this specific subset of tumors, including in Lynch syndrome [73]. Here, CD8A is linked to neoplasm.